Perspective Therapeutics Inc (CATX)

Panoramica Notizia Cronologia dei prezzi Forum Previsione Frazionamento azionario

Perspective Therapeutics Inc Borsa (CATX) Ultime notizie

Perspective Therapeutics Inc (CATX)

Perspective Therapeutics Inc Borsa (CATX) Ultime notizie

Minerva Surgical (NASDAQ:UTRS) versus Perspective Therapeutics (NYSE:CATX) Financial Contrast - Defense World

Perspective Therapeutics: Definitely Not Looking Overvalued Now - Seeking Alpha

Pliant Therapeutics Inc (PLRX): A New Perspective - Stocks Register

Neuroendocrine Tumor Market to Reach New Heights in Growth by 2034, DelveInsight Predicts - News Channel Nebraska

Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials - GlobeNewswire Inc.

Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock faces pivotal moment - Investing.com

BNP Paribas Financial Markets Buys 44,174 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Charles Schwab Investment Management Inc. Acquires 298,778 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat

Walleye Capital LLC Sells 494,706 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat

Perspective Therapeutics, Inc. (NYSE:CATX) Director Acquires $100,003.75 in Stock - MarketBeat

Janus Henderson Group PLC Has $64.01 Million Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat

Fmr LLC Purchases 5,370,392 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat

Perspective Therapeutics CEO Johan Spoor buys $30,132 in stock By Investing.com - Investing.com Canada

Perspective Therapeutics CEO Johan Spoor buys $30,132 in stock - Investing.com India

Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Perspective Therapeutics CFO Jonathan Hunt acquires $48,974 in stock - Investing.com India

Perspective Therapeutics CFO Jonathan Hunt acquires $48,974 in stock By Investing.com - Investing.com Nigeria

Perspective Therapeutics selloff a buying opportunity, says JonesResearch - MSN

Insider Buying: Jonathan Hunt Acquires Shares of Perspective The - GuruFocus.com

Perspective Therapeutics director Robert Williamson acquires shares worth $22,813 - Investing.com

Jonathan Robert Hunt Acquires 12,829 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock - MarketBeat

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December - The Manila Times

Perspective Therapeutics to Present at Piper and Evercore Healthcare Conferences in December | CATX Stock News - StockTitan

Perspective Therapeutics (NYSE:CATX) Rating Lowered to “Neutral” at Bank of America - Defense World

Perspective Therapeutics price target lowered to $9 from $17 at B. Riley - TipRanks

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor Acquires 14,500 Shares - MarketBeat

Perspective Therapeutics CEO Johan Spoor buys $100,468 in stock - Investing.com

Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital - Yahoo Finance

Perspective Therapeutics downgraded to Neutral from Buy at BofA - Yahoo Finance

Perspective Therapeutics (NYSE:CATX) Price Target Cut to $16.00 by Analysts at Oppenheimer - Defense World

Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock faces challenges, opportunities - Investing.com

Perspective Therapeutics shares hold Outperform as RBC adjusts expectations for progress - Investing.com Nigeria

Perspective Therapeutics (NYSE:CATX) Rating Lowered to Neutral at Bank of America - MarketBeat

Autonomix Medical (NASDAQ:AMIX) vs. Perspective Therapeutics (NYSE:CATX) Critical Review - Defense World

Perspective Therapeutics stock downgraded to Neutral By Investing.com - Investing.com Nigeria

Perspective Therapeutics stock downgraded to Neutral - Investing.com India

Perspective Therapeutics price target lowered to $16 from $22 at Oppenheimer - TipRanks

Stock market news: Perspective Therapeutics -44.33%, Pyxis Oncology -42.93% among top losers during mid day trading - Business Upturn

Stock market news: SKK Holdings Limited declined by 51.53% while SCWorx Corp. surged by 101.02% during mid day trading - Business Upturn

Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings - Benzinga

Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn

Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn

Perspective stock slips after radio pharma data (CATX:NYSE) - Seeking Alpha

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium - The Manila Times

Cantor Fitzgerald Has Positive View of CATX FY2024 Earnings - MarketBeat

Simile a CATX